Background {#Sec1}
==========

In patients with cancer, fever in chemotherapy-induced severe neutropenia (FN) is the most frequent potentially lethal complication of chemotherapy for cancer \[[@CR1]\]. When absolute neutrophil count drops below 0.5 × 10^9^/L the risk of life-threatening bacterial infection increases \[[@CR2]\]. Prompt empirical therapy with broad-spectrum antibiotics is standard of care and lethality is below 1% in pediatric patients \[[@CR3], [@CR4]\] and approximately 10% in adult patients \[[@CR5]\], but still FN remains the leading cause of emergency hospitalization. Time to antibiotics (TTA) usually refers to the amount of time passed from arrival at the hospital to administration of antibiotics, and despite inconsistent evidence about the association of TTA and clinical outcomes, guidelines \[[@CR6]--[@CR8]\] and experts insist that timely and appropriate antibiotic administration is essential for adequate patient care. TTA \< 60 min is even used as a measure of quality of care \[[@CR9]\]. Presuming the beneficial effect on patient-important outcomes, several groups have attempted to reduce TTA in patients with FN by implementing specific interventions in emergency departments (ED) and oncology wards. These interventions have never been summarized, so this systematic review aimed to identify and synthesize information on interventions performed, their effect to reduce TTA, and the potential use of these approaches.

Methods {#Sec2}
=======

The protocol for this review was registered on PROSPERO (CRD42018092948) prior to commencing the work and has been published \[[@CR10]\]. Simultaneously with this systematic review, we collected information about the association between TTA and clinical outcomes in patients with FN under chemotherapy for cancer, published separately \[[@CR11]\]. This section is an adapted version of the methods reported there.

Electronic searches of MEDLINE, MEDLINE In-Process & Other Non-Indexed Citations, EMBASE, CINAHL, CDSR, CENTRAL, and LILACS were performed on May 9th, 2018. The search was updated on April 5th, 2019. The search strategy included the Medical Subject Heading terms and text words to identify fever and neutropenia and the intervention of treatment with antibiotics. Antibiotics were additionally searched by groups and names of antibiotic drugs (e.g., penicillin, beta-lactams, quinolones).

In EMBASE search, "time" was added as a required search factor to narrow the results. Studies from 1997 onward were eligible, no language restrictions were applied. Pilot searching took place before the actual search and found all five previous identified studies \[[@CR12]--[@CR16]\]. The full search strategies are provided with the protocol publication \[[@CR10]\]. Manual searches of references and forward citation searching of included articles was conducted. Authors of relevant studies and experts within the field were contacted to seek further studies.

Study selection {#Sec3}
---------------

Inclusion and exclusion criteria were defined a priori. Studies investigating any intervention or combination of interventions attempting to reduce TTA in adult or pediatric patients with cancer, or after hematopoietic stem cell transplantation, and FN were included. Interventions could be implemented in inpatient or outpatient settings, performed by any person included in the FN management. All kind of studies, except case reports and those presented only as abstract or posters, were eligible.

### Outcomes {#FPar1}

Absolute change of TTA was the primary outcome. Secondary outcomes were TTA measurements other than absolute, safety, and treatment adequacy. Safety was defined as death, admission to intensive care unit (ICU), and/or severe sepsis (including septic shock); treatment adequacy was defined as relapse of primary infection, persistence of fever, and/or recurrence of fever without a new infection. Additional clinical outcomes as microbiologically defined infections, days of fever, length of hospital stay (LOS), modification of antibiotics, new infections, and composite outcomes that each individual study selected were recorded.

### Exclusion criteria {#FPar2}

Studies were excluded if (1) they were not specific to cancer or did not report on this subgroup separately (mixed populations were permitted if \> 50% population were diagnosed with cancer/hematopoietic stem cell transplantation); (2) they did not report TTA; (3) they did not have data of an accurate comparator group, defined as cared for in the same way, in the same setting, and with the same treatment regimens, except of the intervention studied. The comparison group could be of the same cohort and could be observed simultaneously or successively.

### Screening {#FPar3}

One reviewer (CK) screened the title and abstract of all studies for inclusion. A second reviewer (CS) independently screened 60% of the titles and abstracts. The kappa statistic for agreement was calculated and showed good agreement between reviewers (*k* = 0.91, 95% confidence interval (CI) 0.87 to 0.94). Full text was obtained for all potential articles of interest. All full texts were assessed for eligibility by two reviewers (CK and CS; *k* = 0.79, 95% CI 0.69 to 0.89). Fourteen studies were referred to a third reviewer (RSP), where 11 were excluded.

Data extraction and risk of bias assessment {#Sec4}
-------------------------------------------

Data extraction and risk of bias assessment was done by one reviewer (CK) and independently checked by a second (RAA). Discrepancies were resolved by consensus. Intervention characteristics were collected according to the Cochrane Effective Practice and Organization of Care Review Group (EPOC) data collection checklist \[[@CR17]\]. Risk of bias was assessed using the Risk of Bias in Non-randomized Studies of Interventions (ROBINS-I) tool \[[@CR18]\] at the level of the individual study. All articles were included in the review irrespective of the risk of bias.

Statistical methods {#Sec5}
-------------------

Due to heterogeneity within the implemented interventions, study sites, and participants, meta-analysis was not undertaken and a narrative synthesis was performed. To visually display the results of the primary outcome, reduction of TTA, a forest plot was drawn including all studies for which mean and standard deviation (SD) were reported or could be estimated. In studies only reporting median, interquartile range (IQR) or 95% confidence intervals of the mean, and SD were estimated assuming a normal distribution ($\documentclass[12pt]{minimal}
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                \begin{document}$$ \mathrm{median}=\mathrm{mean};\mathrm{SD}=\mathrm{IQR}/1.35;\mathrm{SD}=95\%\mathrm{CI}/3.92\times \sqrt{n} $$\end{document}$) \[[@CR19]\].

Results {#Sec6}
=======

Overview {#Sec7}
--------

Titles and abstracts from 6296 studies were assessed and 177 full-text articles retrieved. A flow diagram of the study selection is provided in Fig. [1](#Fig1){ref-type="fig"}. Thirty studies were included, thirteen in adult \[[@CR12], [@CR20]--[@CR31]\], and seventeen in pediatric patients \[[@CR16], [@CR32]--[@CR47]\], including a total of 1891 and 6820 FN episodes, respectively. Two-third of the studies were undertaken in the USA (*n* = 20; 67%). There were four multicenter studies (included number of centers, 2 to 4) and the vast majority of studies were undertaken in academic hospitals (*n* = 25; 83%). No randomized or quasi-randomized trials were identified by the searches. Before and after studies were the most commonly used design (*n* = 29; 97%), in which TTA was evaluated at baseline and after the implementation of an intervention. Various studies collected TTA at multiple time points, but none of them performed an interrupted time series analysis. The remaining study was a retrospective cohort study \[[@CR26]\].Fig. 1PRISMA flow diagram of identification and selection of eligible studies

Characteristics of included studies are given in Table [1](#Tab1){ref-type="table"}. Most of the interventions were implemented at EDs (26; 87%). Fever was defined within a temperature range of ≥ 38.0 to ≥ 38.5 °C. Seventeen studies defined neutropenia as an absolute neutrophil count (ANC) \< 0.5 × 10^9^/L and/or \< 1.0 × 10^9^/L expected to decrease. Four studies defined neutropenia as ANC \< 1.0 × 10^9^/L. Other definitions were leucocyte count ≤ 4.0 × 10^9^/L or \< 1.0 × 10^9^/L, ANC \< 0.2 × 10^9^/L, or \< 0.58 × 10^9^/L and expected to decrease. TTA was measured from triage or arrival at the hospital to first dose of antibiotics in the majority of studies (*n* = 26; 87%). One study with adult patients started measurement of time at fever detection \[[@CR30]\], one study defined TTA as time from initial provider evaluation to intravenous antibiotic administration, \[[@CR44]\], and the third study started measurement at ICU admission \[[@CR32]\]. In one study, a definition was lacking \[[@CR36]\]. The definitions used per study are displayed in Online Resource [1](#MOESM1){ref-type="media"}, Table [1](#Tab1){ref-type="table"}.Table 1Characteristics of included studies. Italicized data has been calculated by combining data from two armsStudyYearCountrySingle orData collectionIntervention design defined by each study authorsSettingFN episodesAssessedpub(language)multisiteEDOutpatient unitInpatient unit(patients)risk of biasAdult patients  Baltic et al. \[[@CR20]\]2002USA (E)Single siteRetrospectiveQuality improvement projectYesYesYes*11*Serious  Best et al. \[[@CR21]\]2011USA (E)Single siteRetrospectivePractice change processYesNoYes*53 (53)*Moderate  Dang et al. \[[@CR22]\]2018USA (E)Single siteProspectiveDefine, measure, analyze, improve, control (DMAIC) process improvement projectYesNoNo*216 (216)*Serious  Hawley et al. \[[@CR23]\]2011USA (E)Single siteRetrospectiveMultidisciplinary Team ProjectYesYesNo42 (42)Serious  Kapil et al. \[[@CR12]\]2016Canada (E)Single siteRetrospectiveFever advisory cards implementationYesNoNo*308 (308)*Moderate  Keng et al. \[[@CR24]\]2015USA (E)Single siteRetrospective and prospectiveImplementation of a FN PathwayYesNoNo497(386)Low  Ko et al. \[[@CR25]\]2015China (E)Single siteRetrospectiveImplementation of protocolYesNoNo69 (69)Moderate  Lim et al. \[[@CR26]\]2012Canada (E)MultisiteRetrospectiveElectronic clinical practice guideline implementationYesNoNo*201 (201)*Serious  Lim et al. \[[@CR27]\]2013China (E)Single siteRetrospectiveChanges to improve performanceYesYesNo*62 (62)*Moderate  Meisenberg et al. \[[@CR28]\]2015USA (E)Single siteRetrospectivePerformance improvement projectYesYesYes*69 (69)*Moderate  Salter et al. \[[@CR29]\]2005Australia (E)Single siteRetrospectivePathway implementationYesNoNo*35*Serious  Van Vliet et al. \[[@CR30]\]2011Netherlands (E)Single siteProspectiveStrategies for improvementNoYesNo*187 (167)*Moderate  Wells et al. \[[@CR31]\]2015UK (E)Single siteRetrospective and prospectiveService developmentsYesYesYes*141*SeriousPediatric patients  Amado et al. \[[@CR32]\]2011Brazil (E)Single siteRetrospectiveQuality improvement projectNoNoICU45 (45)Moderate  Benner et al. \[[@CR33]\]2016USA (E)Single siteRetrospectiveQuality improvement projectYesNoNo253 (111)Moderate  Cash et al. \[[@CR34]\]2014USA (E)Single siteRetrospectiveImplementation of standardized processYesNoNo130Serious  Cohen et al. \[[@CR35]\]2016USA (E)Single siteRetrospective and prospectiveProtocol initiationYesNoNo*253 (253)*Moderate  Corey et al. \[[@CR36]\]2008USA (E)Single siteRetrospective and prospectivePlan-do-study-act cycleNANANA61Serious  Dobrasz et al. \[[@CR37]\]2013USA (E)MultisiteRetrospectiveEvidence-based practice change, quality initiativeYesNoNo2768Serious  Emerson et al. \[[@CR38]\]2018USA (E)Single siteRetrospective and prospectivePlan-do-study-act cyclesYesNoNo80 (80)Serious  Lamble et al. \[[@CR39]\]2015USA (E)Single siteRetrospectiveClinical care pathway implementationYesNoNo*476(250)*Moderate  Lukes et al. \[[@CR40]\]2019USA (E)Single siteRetrospectiveQuality improvement projectYesNoNo101 (101)Moderate  Monroe et al. \[[@CR41]\]2018USA (E)Single siteRetrospective and prospectiveQuality improvement projectYesNoNoNASerious  Pakakasama et al. \[[@CR42]\]2011Thailand (E)Single siteRetrospectiveEstablishment of clinical practice guidelinesYesNoNo*308 (162)*Serious  Salstrom et al. \[[@CR16]\]2015USA (E)Single siteRetrospective and prospectiveQuality improvement projectYesNoYes*116 (116)*Moderate  Spencer et al. \[[@CR43]\]2017USA (E)MultisiteRetrospectiveQuality improvement projectYesNoNo1032 (1032)Moderate  Vanderway et al. \[[@CR44]\]2017USA (E)Single siteRetrospective and prospectiveQuality improvement projectNoYesNo*25 (25)*Moderate  Vedi et al. \[[@CR45]\]2015Australia (E)MultisiteRetrospectiveAlgorithm-based approachYesNoNo*89 (89)*Moderate  Volpe et al. \[[@CR46]\]2012USA (E)Single siteRetrospectiveQuality improvement project, plan-do-study act cycleYesNoNo*365 (365)*Low  Yoshida et al. \[[@CR47]\]2018USA (E)Single siteProspective2-phase quality improvement projectYesNoNo718 (327)Moderate*E*, English; *ED*, emergency department; *FN*, fever and neutropenia; *ICU*, intensive care unit; *NA*, not available; *pub*, published

Risk of bias {#Sec8}
------------

Study quality and risk of bias assessment identified a moderate or serious risk for bias in all but two of the included studies (Table [1](#Tab1){ref-type="table"}, for full assessment: Online Resource [1](#MOESM1){ref-type="media"}, Table [2](#Tab2){ref-type="table"}). Potential confounders for TTA were set at FN diagnosis, localization of presentation (ED versus oncology ward versus oncology outpatient unit), high patient volumes, presence of central line, and knowledge of staff about an ongoing study (Hawthorne effect) \[[@CR32]\]. Additionally, risk status of patients, initial illness severity, time of presentation, and administration route of antibiotics were identified as possible but measurable confounders in almost all studies.Table 2Intervention and time to antibiotics reduction in the included studiesStudyType of interventionStaff educationChecklist/guidelinesFollow-upTTA before intervention (mean)TTA after intervention (mean)Absolute TTA\
reduction% TTA reduction% with TTA ≤ 60 min before/afterProfessionalOrganizationalProviderPatientStructuralBaltic et al. \[[@CR20]\]YesYesYesYesYesYesNo188 min64 min124 min66%NABest et al. \[[@CR21]\] (1)Best et al. \[[@CR21]\] (2)YesNoNoYesYesYesNo188 min115 min73 min38%NAYesNoNoYesYesYesNo228 min163 min65 min29%Dang et al. \[[@CR22]\]YesYesYesYesYesYesNo100 min27 min73 min73%31%/95.5%Hawley et al. \[[@CR23]\] (1)YesYesYesYesYesYesNo138 min91.6 min46.4 min34%NAHawley et al. \[[@CR23]\] (2)YesYesYesYesYesYesNo70 min52.6 min17.4 min25%NAKapil et al. \[[@CR12]\]YesNoNoNoNoNoNo244 min195 min49 min20%NAKeng et al. \[[@CR24]\]YesNoNoYesYesYesNo235 min\*81 min\*154 min66%1%/32%Ko et al. \[[@CR25]\]NoNoNoYesNAYesNo300 min47 min253 min84%0 to 86%Lim et al. \[[@CR26]\]YesNoNoNoYesYesNo4.9 h\*3.9 h\*1 h20%NALim et al. \[[@CR27]\]YesYesNoYesYesYesNo261 min \*95 min\*166 min64%NAMeisenberg et al. \[[@CR28]\]YesNoYesYesYesYesNo252 min\*117 min\*135 min54%NASalter et al. \[[@CR29]\]NoYesNoYesNoYesNo3.8 h\*3.45 h\*0.35 h9%NAVan Vliet et al. \[[@CR30]\]NoYesNoYesNoNoYes75.1 min32.0 min43.1 min57%NAWells et al. \[[@CR31]\]YesYesNoYesYesYesNoNANANANA31%/79%Amado et al. \[[@CR32]\]NoNoNoYesNoNoNo164 min55 min109 min66%0%/52%Benner et al. \[[@CR33]\]YesYesYesYesYesYesYes207 min\*88.5 min\*118.5 min57%0.9%/67%Cash et al. \[[@CR34]\]YesYesNoYesYesYesNo154 min\*95 min\*59 min38%2%/3%Cohen et al. \[[@CR35]\]YesYesYesYesYesYesYes96.9 min69.5 min27.4 min28%35%/51.4%Corey et al. \[[@CR36]\]YesYesNoYesYesNoYesTTA only graphically reportedNANANADobrasz et al. \[[@CR37]\] (1)Dobrasz et al. \[[@CR37]\] (2)YesYesNoYesYesYesYes89 min44 min45 min51%NAYesYesNoYesYesYesYes110 min61 min49 min45%NAEmerson et al. \[[@CR38]\]YesYesYesYesYesYesNo116 min55 min61 min53%NALamble et al. \[[@CR39]\]YesNoNoYesYesYesYes115 min\*60 min\*55 min48%12%/46%Lukes et al. \[[@CR40]\]YesYesNoYesYesNoYes108 min\*47 min\*61 min56%17%/83%Monroe et al. \[[@CR41]\]YesYesYesYesYesYesNoNANANANA30%/80.4%Pakakasama et al. \[[@CR42]\]YesYesNoYesYesYesNo180 min\*75 min\*105 min58%NASalstrom et al. \[[@CR16]\]YesNoYesYesYesNoYes164 min45.2 min119 min73%19 to 74%Spencer et al. \[[@CR43]\] (1)Spencer et al. \[[@CR43]\] (2)Spencer et al. \[[@CR43]\] (3)YesYesYesYesNAYesYes118.5 min\*57 min\*61.5 min52%NAYesYesYesYesNAYesYes163 min\*97.5 min\*65.6 min40%NAYesYesYesYesNAYesYes188 min\*111.5 min\*76.5 min41%NAVanderway et al. \[[@CR44]\]YesYesNoYesYesYesNo79.6 min41.2 min38.4 min48%NAVedi et al. \[[@CR45]\] (1)Vedi et al. \[[@CR45]\] (2)YesYesNoYesYesYesYes148 min76 min72 min49%0 to 35%YesYesNoYesYesYesYes221 min65 min156 min71%NAVolpe et al. \[[@CR46]\]YesYesNoYesYesNoNo99 min49 min50 min51%50%/88.5%Yoshida et al. \[[@CR47]\]YesYesNoYesYesYesNo83 min65 min18 min22%47%/69%*ED*, emergency department; *NA*, not available; *ICU*, intensive care unit; *TTA*, time to antibiotics; \*Median

Interventions {#Sec9}
-------------

Various types of interventions were implemented, most of the studies made more than one single intervention. Among the thirty studies, the most common group of intervention targeted professionals. They consisted of distribution of FN-Alert cards to patients, skills training, education for staff, and educational updates or feedbacks. Twenty-two studies implemented guidelines, algorithms, or checklists for FN treatment. The collected interventions are summarized in Online Resource [1](#MOESM1){ref-type="media"}, Table [3](#Tab3){ref-type="table"}. No study used regulatory or financial interventions.Table 3Sources of delays (number of studies reporting) in adult and pediatric patientsAdult patientsPediatric patientsStaff relatedStaff related  • Lack of awareness of potential risk/knowledge about FN (5)  • FN patients not recognized (3)  • Difficulties in obtaining central venous access (3)  • Long waiting time for phlebotomist to set up the intravenous line (1)  • Long turn-around time from setting of the prescription by pharmacist to drug dispensing (1)  • Antibiotics not scheduled as urgency by pharmacist (1)  • Lack of staff (1)  • Long waiting time for initial physician assessment (3)  • Delay related to waiting for a second medical review (1)  • Physician trainees involved in care (1)  • Communication issues (1)• Lack of awareness of potential risk/knowledge about FN (2)• FN patients not recognized (1)• Difficulties in obtaining central venous access due to lack of training/technical difficulties (4)• No physician available (for examination or order for antibiotics) (4)• Lack of expertise, fear of treating oncology patients (3)• Communication with specialist/staff (3)Patient relatedPatient related  • Lack of knowledge of patients (1)• Difficulties in obtaining central venous access due to inadequate topical analgesia (3)• Difficulties in obtaining central venous access due to parents requesting specific nurses/other expectations (3)Procedure relatedProcedure related  • Lack of a triage system (1)  • Unavailability of laboratory results (4)  • Missing FN protocols (1)  • Absence of order set (2)  • Large number of patients, multiple concomitant admissions (1)  • Antibiotics not available at emergency (1)  • Delayed administration of antibiotics due to structural issues (3) (after transfer to inpatient unit, only on next drug round)  • Lack of access to important patient information (1)  • Day of the week (1)• Unawareness of patient arrival (1)• Difficulties in obtaining central venous access due to lack of equipment (1)• Unavailability of laboratory results (6)• Antibiotics not available at emergency (5)• Two separate policies for BMT and non-BMT patients (1)• ED crowding/Competing unwell patients (1)• No exam/infusion room available, room not prepared (2)• Guidelines not accessible (1)• Patient information cannot be entered into the computer system until the patient's arrival on the unit (1)• Lack of access to important patient information (1)*BMT*, bone marrow transplant; *ED*, emergency department; *FN*, fever and neutropenia

The studies were indexed to setting, type of intervention, education of staff, implementation of guidelines, algorithms or checklists, and whether they had a follow-up or not (Table [2](#Tab2){ref-type="table"}). Online Resource [1](#MOESM1){ref-type="media"}, Table [3](#Tab3){ref-type="table"} gives an overview of the applied interventions. The number of intervention events varied from 1 to 7, and duration of intervention was from one single intervention point up to 3 years. Interventions were provided and delivered by local physicians, nurses, pharmacist, laboratory staff, and employees from administration and hospital bed control. One study was supported by hospital quality improvement experts \[[@CR46]\] and one by members of the Information Technology department \[[@CR40]\]. Unit of allocation and analysis were always the individual patients, and the purpose of recommendation was always appropriate management of these patients.

Targeted behaviors were diagnosis (*n* = 13), test ordering (*n* = 6), procedures (*n* = 19), prescribing (*n* = 12), general management of a problem (*n* = 19), patient education/advice (*n* = 11), and communication between professionals (*n* = 8). To address them, various formats were used like interpersonal, paper, visual, computer, paging system, and phones.

Several articles identified sources of delays and barriers to improve TTA; these are presented separately between adult and pediatric studies in Table [4](#Tab4){ref-type="table"}.Table 4Barriers to change (number of studies reporting) in adult and pediatric patientsAdult patientsPediatric patientsStaff relatedStaff related  • Disempowerment of clinicians diagnosing and caring for the patient (1)  • Lack of understanding, ignorance or stubbornness, concerns with lack of autonomy (physician) (2)  • Lack of order set compliance, low guideline usage (2)  • Lack of communication between professionals (1)  • Lack of ongoing education (1)  • ED overcrowding, (not enough staff) (1)• Persisting mind-set to confirm neutropenia before antibiotics (1)• False sense of security: "just another FN patient" (1)• Lack of knowledge due to rotating residents/medical students (1)• Education difficulties due to part-time and rotate shifts (2)• Lack of guideline compliance (3)• Forgetting the availability of standard dose of antibiotics (1)• Overwhelming workload, priorities for other patients (2)Patient relatedPatient related  • Fever alert card unsuitable for some patients (to big, neglect the replacement of a full card) (1)  • Inadequate consultations/intolerance of patients (1)• Patient/parents preferences of staff for central venous access (2)Procedure relatedProcedure related  • Lack of communication of order-set-availability (1)• Institution not used to standardized processes (1)• State regulation (protocol cannot be initiated before an attending physician assumes care for a patient) (1)• Already close to target before intervention (1)*ED*, emergency department; *FN*, fever and neutropenia

Reduction of TTA {#Sec10}
----------------

All 28 studies that compared TTA before and after an intervention reported a reduction in TTA after the intervention (Table [2](#Tab2){ref-type="table"}). Only one of these studies \[[@CR12]\], performed in adults, reports a statistically non-significant result, even when TTA declined from a mean of 244 to 195 min (*p* = 0.09). This study was judged at moderate risk for bias. One study displayed TTA only graphically \[[@CR36]\], but equally shows a reduction of TTA. The remaining retrospective cohort study \[[@CR26]\] compared TTA in four different hospitals while the intervention was only implemented in one. Likewise, this study showed a significant shorter TTA in the intervention hospital (3.9 versus 4.9 h, *p* = 0.02).

TTA is reported as continuous variable in all but two studies \[[@CR31], [@CR41]\]. These specific studies only report an increase in percentage of patients treated within 60 min, as it was reported by several other studies, in addition to continuous TTA (Table [2](#Tab2){ref-type="table"}). The relative reduction of TTA is displayed in Fig. [2](#Fig2){ref-type="fig"} for studies reporting mean and SD or when those parameters could be estimated.Fig. 2Relative reduction in TTA of studies reporting mean and standard deviation or when those parameters could be estimated

Clinical outcomes {#Sec11}
-----------------

### Safety {#FPar4}

Most studies were underpowered to address safety (mortality, ICU admission, or occurrence of severe sepsis). Number of deaths was reported by eleven studies \[[@CR16], [@CR24], [@CR25], [@CR31], [@CR33], [@CR35], [@CR36], [@CR39], [@CR42], [@CR43], [@CR46]\], with a median mortality of 0% (maximum 39%) before and median mortality of 0% (maximum 6%) after the intervention. No significant differences of mortality before and after intervention were detected in seven of these 11 studies. One study only reported the overall number of deaths \[[@CR43]\]. One study \[[@CR25]\] found an increase in mortality from 0 (0/19 episodes) to 6% (3/50 episodes; *p* \< 0.05), but these are equally low numbers of deaths and no significant difference was found when death was included into a composite outcome together with serious medical complications (1/19 versus 7/50; *p* = 0.45). A decrease in mortality was shown in two studies \[[@CR31], [@CR42]\]. For adult patients, Wells et al. \[[@CR31]\] report a high mortality of 39% (14 of 36 episodes) before and a mortality of 0% (0 of 79 episodes) after their intervention. Their intervention increased the percentage of patients treated within 60 min from 14 to 79%, but no absolute times are reported. For pediatric patients, Pakakasama et al. \[[@CR42]\] reports a significant reduction in mortality from 6.5 (9 of 138 episodes) before to 0% (0 of 170 episodes; *p* = 0.001) after the implementation of guidelines. In their study, ICU admission and septic shock were as well significantly reduced after the implementation, 9.4 to 2.9% (*p* = 0.016) and 10.9 to 3.5% (*p* = 0.011), respectively.

Numbers of ICU admissions were reported by eight studies \[[@CR24], [@CR25], [@CR33], [@CR35], [@CR36], [@CR39], [@CR42], [@CR46]\], with a median of 5% (maximum 9%) before and a median of 1.3% (maximum 7%) after the intervention. Only one study \[[@CR16]\] found a difference in need for ICU admission before and after the intervention (34% versus 12.8%; *p* \< 0.05). This study describes extending the study period when the results were not significant, without describing the number or nature of the interim analyses. Sepsis was additionally analyzed by one adult study \[[@CR25]\], where almost all patients before (84%) and after the intervention (90%) were diagnosed with sepsis.

### Treatment adequacy {#FPar5}

No study reported relapses of primary infection, persistence of fever for more than 5 days, or recurrence of fever without a new infection.

### Additional outcomes {#FPar6}

Numbers of patients with an identified source of infection/bacteremia were comparable within the investigated groups before and after the intervention in all studies that analyzed these \[[@CR16], [@CR24], [@CR27], [@CR39], [@CR42]\]. Likewise none of three studies with data about duration of fever found a significant difference within the groups \[[@CR16], [@CR25], [@CR32]\].

For length of hospital stay (LOS), five studies \[[@CR24], [@CR25], [@CR27], [@CR29], [@CR33]\] did not find a significant difference before and after the intervention. In one of those studies \[[@CR24]\], LOS was reduced after an intervention when compared with a historical cohort in a multivariable analysis that adjusted for age, disease type, MASCC risk index, prophylactic antibiotics, central line, and ANC, but not in univariate analysis. Only the pediatric study of Pakakasama et al. \[[@CR42]\], who described improved safety, showed that LOS decreased significantly after the intervention. Median LOS was 5 days (range, 1--30 days) in the 170 episodes of the intervention group, whereas it was 7 days (range, 1--170 days) in the 138 episodes of the control group (*p* = 0.001). In one study \[[@CR21]\], LOS was shorter before (mean 11.33 days; *n* = 30) than after the intervention (mean 17.43 days; *n* = 23). The authors explain this finding by low number of patients and outliers due to unequal groups. Modification of antibiotics and new infections were not reported by any study.

Subgroup analyses {#Sec12}
-----------------

Only the planned subgroup analyses between pediatric and adult patients were possible to be undertaken. The main finding was different sources of delays in these two groups (Table [3](#Tab3){ref-type="table"}). Regardless of these different barriers, the durations and reductions were broadly similar: TTA before an intervention varied between an average (median or mean) of 70--300 min in adult studies and 79.6--221 min in pediatric studies. After an intervention, adult studies showed TTAs between 27 and 234 min and pediatric studies between 41.2--111.5 min. Reduction of the average TTA was between 17.8--253 min (or 9--84%) in adult and 18--156 min (or 22--73%) in pediatric studies.

Discussion {#Sec13}
==========

TTA can be effectively reduced by very different interventions in a wide range of practice settings in both pediatric and adult patients with fever and neutropenia during chemotherapy for cancer. Most of the identified interventions were aimed at modifying the behavior of professionals and implemented at EDs; implementation of guidelines or a checklist were the most often used strategies. Although it is reasonable to assume that publication bias strongly influences this result if only effective interventions are reported, this systematic review helps to identify possible sources of delays and summarizes different strategies to address them.

Guidelines or checklists are useful to address patient-, procedure-, and staff-related factors at once and they were used by 77% of the included studies. Whereas patient- and procedure-related factors may be more difficult to address otherwise, staff-related factors can be resolved by regular education and training. Unsurprisingly, staff-related factors were also a common reason for delays of TTA and professional interventions were very often used. A systematic review evaluating effective knowledge translation strategies in cancer \[[@CR48]\] found that the most promising interventions were professional ones, like educational outreach, audits, and feedbacks. In line with these results, our systematic review supports the fact that education and training remain core elements for a successful reduction in TTA. One study showed a reduction in median TTA about 1 h, only by informing staff about already existing guidelines \[[@CR26]\]. Unfortunately staff-related issues were also the most often identified barriers to change (Table [4](#Tab4){ref-type="table"}).

Published interventions without professional approaches were all organizational: standing orders allowing nurses to administer antibiotics before calling a physician \[[@CR29], [@CR30]\], making antibiotics rapidly available \[[@CR32]\], and implementation of a treatment protocol without emphasizing staff education \[[@CR25]\]. Among them was the study with the largest TTA reduction \[[@CR25]\], with a reduction of mean TTA by 253 min, keeping in mind that this study also reports the longest TTA before the organizational change (mean 300 min).

Presentation at the ED has been identified as a reason for longer TTA \[[@CR15], [@CR49]\] and more frequent adverse events \[[@CR14]\]. This matches our finding that 26 (87%) of the identified studies were undertaken in EDs. High workload due to high patient volumes and lack of training in care of oncology patients may explain this. Three included studies \[[@CR26], [@CR34], [@CR47]\] mentioned ED overcrowding and lack of staff as a barrier to changes; these are factors difficult to address by physicians but should be acknowledged by institutions, where identified.

A study from Canada \[[@CR50]\] identified age \> 60 years and lack of caregiver as a risk factor for delayed TTA. In our review, only three studies identified patient-related factors as barriers to change; this may reflect the largely positive input of patients or lack of specific research into these issues.

There were several challenges to summarizing the primary data sources. Through differences in the definitions of key study variables, it was not possible to identify specific interventions that are more likely to be effective than others. The studies were undertaken in different countries and their results must be interpreted in the context of different healthcare provisions. Additionally, the interventions were uneven with respect to type of intervention, number and duration of interventions, what person delivered the intervention, target of behavior, and format used. Because often a number of changes were instituted simultaneously, it is not possible to determine the impact of any single change.

Almost all studies were before and after studies. The identified Hawthorne effect (knowledge of staff about an ongoing study) may have an important influence and therefore follow-up assessments after the intervention should be undertaken to see whether the improvements are sustainable. Outcomes, such as TTA, may change over time for reasons unrelated to the implemented strategy. If repeated observations before and after an intervention are available, the more robust interrupted time series analysis should be conducted \[[@CR51]\]. Assessment of clinical outcomes was limited due to low numbers. Additionally, inclusion of patients at different risk for medical complications creates a triage bias, i.e., faster treatment of patients with worse clinical condition \[[@CR11]\] and may therefore mask an effect of shorter TTA in the included studies.

The key strength of this manuscript lies in its thorough application of systematic review methodology. It thus provides the most complete summary of interventions aiming to reduce TTA in patients with FN during chemotherapy for cancer. Additionally, it provides a clearly arranged list of sources of delays and barriers to change TTA, and the undertaken risk of bias assessment helps to judge the validity of the results in TTA reduction.

Conclusion {#Sec14}
==========

TTA can be effectively reduced by very different interventions; however, the direct impact of a shorter TTA on clinical outcomes could not be determined. Education and training were identified as core elements to successfully reduce TTA and remain essential to improve quality of care. Some centers already defined TTA ≤ 60 min as a valid measure of quality of care \[[@CR9], [@CR24]\], and although the clinical implication of a shorter TTA is not yet clear \[[@CR11]\], our results support the assertion that TTA can be considered a measure of quality of care. This systematic review can be used by care teams as a checklist to identify sources of delays and to evaluate what may be the most important and effective intervention to implement in their specific center to reduce TTA.
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